LEADER 01236nam  2200373Ia 450 
001 9910699379103321
005 20230902162200.0
035   $a(CKB)5470000002402122
035   $a(OCoLC)499058546
035   $a(EXLCZ)995470000002402122
100   $a20100115d2008      ua             0
101 0 $aeng
135   $auran|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGuidance for industry$b[electronic resource] $ehypertension indication, drug labeling for cardiovascular outcome claims
210  1$aSilver Spring, MD :$cU.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research,$d[2008]
215   $a1 online resource (7 pages)
300   $a"Labeling."
300   $a"March 2008."
320   $aIncludes bibliographical references (page 7).
517   $aGuidance for industry 
606   $aHypertension
606   $aDrugs$xLabeling
615  0$aHypertension.
615  0$aDrugs$xLabeling.
712 02$aCenter for Drug Evaluation and Research (U.S.)
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910699379103321
996   $aGuidance for industry$93434577
997   $aUNINA